摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-碘-5-甲氧基吡啶 | 163129-79-1

中文名称
2-碘-5-甲氧基吡啶
中文别名
——
英文名称
2-iodo-5-methoxypyridine
英文别名
3-methoxy-6-iodopyridine
2-碘-5-甲氧基吡啶化学式
CAS
163129-79-1
化学式
C6H6INO
mdl
MFCD02259696
分子量
235.024
InChiKey
PTKTXYDJIOBEOD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    262.1±25.0 °C(Predicted)
  • 密度:
    1.825±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

SDS

SDS:2229583644c146da22fdd1dd0785ada7
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Iodo-5-methoxypyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Iodo-5-methoxypyridine
CAS number: 163129-79-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6INO
Molecular weight: 235

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-碘-5-甲氧基吡啶 在 palladium diacetate 、 氢氧化钾四丁基氯化铵potassium carbonate 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 反应 32.0h, 生成 (E)-3-(2-methoxy-6-pyridinyl)acrylic acid
    参考文献:
    名称:
    New Water-Soluble Duocarmycin Derivatives: Synthesis and Antitumor Activity of A-Ring Pyrrole Compounds Bearing β-Heteroarylacryloyl Groups
    摘要:
    A series of A-ring pyrrole compounds of duocarmycin bearing 4'-methoxy-beta-heteroarylacryloyl groups were synthesized and evaluated for in vitro anticellular activity against HeLa S-3 cells and in vivo antitumor activity against murine sarcoma 180 in mice. Most of the Li 4'-methoxy-beta-heteroarylacrylates displayed in vitro anticellular activity equivalent to that of 4'-methoxycinnamates, Among the 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates, compound 15b having a (4-methoxy-3,5-pyrimidinyl)acryloyl as segment-B (Seg-B) showed remarkably potent in vivo antitumor activity and low peripheral blood toxicity compared with the A-ring pyrrole derivatives having the trimethoxyindole skeleton in Seg-B, which were equal to 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxycinnamates. Moreover, these 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates had high aqueous solubility.
    DOI:
    10.1021/jm980559y
  • 作为产物:
    描述:
    甲醇2-碘-5-羟基吡啶sodium methylate 作用下, 以100%的产率得到2-碘-5-甲氧基吡啶
    参考文献:
    名称:
    New Water-Soluble Duocarmycin Derivatives: Synthesis and Antitumor Activity of A-Ring Pyrrole Compounds Bearing β-Heteroarylacryloyl Groups
    摘要:
    A series of A-ring pyrrole compounds of duocarmycin bearing 4'-methoxy-beta-heteroarylacryloyl groups were synthesized and evaluated for in vitro anticellular activity against HeLa S-3 cells and in vivo antitumor activity against murine sarcoma 180 in mice. Most of the Li 4'-methoxy-beta-heteroarylacrylates displayed in vitro anticellular activity equivalent to that of 4'-methoxycinnamates, Among the 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates, compound 15b having a (4-methoxy-3,5-pyrimidinyl)acryloyl as segment-B (Seg-B) showed remarkably potent in vivo antitumor activity and low peripheral blood toxicity compared with the A-ring pyrrole derivatives having the trimethoxyindole skeleton in Seg-B, which were equal to 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxycinnamates. Moreover, these 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates had high aqueous solubility.
    DOI:
    10.1021/jm980559y
  • 作为试剂:
    描述:
    5-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenoxymethyl]furan-2-carboxylic acid methyl ester2-碘-5-甲氧基吡啶2-碘-5-甲氧基吡啶 作用下, 生成 4-[4-(5-methoxypyridin-2-yl)phenoxymethyl]-5-methylfuran-2-carboxylic acid methyl ester
    参考文献:
    名称:
    EP4 receptor antagonists
    摘要:
    化合物的化学式为(I):其中:R2为H或可选择性取代的C1-4烷基;Y为—(CH2)n—X—,其中n为1或2,X为O,S,S(═O),S(═O)2或NRN1,其中RN1为H或可选择性取代的C1-4烷基,或Y为—C(═O)NRN2—,其中RN2为H,可选择性取代的C1-7烷基或C5-20芳基;R3为可选择性取代的C6芳基基团,与另一个可选择性取代的C6芳基基团相连,如果两个C6芳基基团都是苯环,则两个环之间可能有一个氧桥,与两个环上的连接相邻;A为单键或C1-3烷基;R5为:(i)羧基;(ii)式(II)的基团:或(iii)式(III)的基团:其中R为可选择性取代的C1-7烷基,C5-20芳基或NRN3RN4,其中RN3和RN4独立地选择可选择性取代的C1-4烷基;(iv)四唑-5-基基团。
    公开号:
    US07196089B2
点击查看最新优质反应信息

文献信息

  • [EN] BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE<br/>[FR] DERIVES D'AMIDE HETEROARYLE BENZOCONDENSE DE THIENOPYRIDINES UTILISEES EN TANT QU'AGENTS THERAPEUTIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES D'UTILISATION ASSOCIES
    申请人:PFIZER
    公开号:WO2003106462A1
    公开(公告)日:2003-12-24
    The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    该发明涉及由公式I表示的化合物,以及这些化合物的前药或代谢物,或者这些化合物的药用可接受的盐或溶剂化合物,所述前药和代谢物,其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物,以及通过给予公式I化合物来治疗哺乳动物的增殖过度性疾病的方法。
  • Lithium trihydroxy/triisopropoxy-2-pyridylborate salts (LTBS): synthesis, isolation, and use in modified Suzuki–Miyaura cross-coupling reactions
    作者:Kuanchiang Chen、Richard Peterson、Shivanand K. Math、James B. LaMunyon、Charles A. Testa、Dustin R. Cefalo
    DOI:10.1016/j.tetlet.2012.06.145
    日期:2012.9
    and triisopropoxy 2-borate salts (LTBS) for use in modified Suzuki–Miyaura cross-coupling reactions that can be produced in quantities greater than one hundred grams. Pyridyl LTBS provide a viable cross-coupling alternative to unstable 2-pyridylboronic acids, boronates, and trifluoroborate salt derivatives. We also demonstrate the synthesis and cross-coupling of shelf-stable LTBS reagents of other sp2-hybridized
    我们在本文中描述了可用于修饰的Suzuki-Miyaura交叉偶联反应的货架稳定,可分离且可表征的吡啶基锂三羟基和三异丙氧基2-硼酸盐(LTBS),其用量可大于100克。吡啶基LTBS为不稳定的2-吡啶基硼酸,硼酸盐和三氟硼酸盐衍生物提供了可行的交叉偶联选择。我们还证明了其他sp 2-杂化的含氮杂环,包括噻唑,吡嗪,喹啉和异喹啉杂环的货架稳定LTBS试剂的合成和交叉偶联。
  • Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
    申请人:Agouron Pharmaceuticals, Inc.
    公开号:US20040009965A1
    公开(公告)日:2004-01-15
    The invention relates to compounds represented by the formula I 1 and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R 11 and R 14 , R 15 , R 16 , and R 17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    这项发明涉及由公式I1表示的化合物,以及这些化合物的前药或代谢物,或这些化合物的药用可接受的盐或溶剂,所述前药和所述代谢物,其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物,以及通过给哺乳动物施用公式I化合物来治疗过度增殖性疾病的方法。
  • [EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
    申请人:NIMBUS LAKSHMI INC
    公开号:WO2015131080A1
    公开(公告)日:2015-09-03
    The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    本发明提供了化合物、其组合物以及使用这些化合物抑制TYK2并治疗TYK2介导的疾病的方法。
  • [EN] EP4 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES AUX RECEPTEURS EP4
    申请人:PHARMAGENE LAB LTD
    公开号:WO2004067524A1
    公开(公告)日:2004-08-12
    Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl.
    式(I)的化合物:其中:R2为H或可选择地取代的C1-4烷基基团;Y为-(CH2)n-X-,其中n为1或2,X为O、S、S(=O)、S(=O)2或NRN1,其中RN1从H或可选择地取代的C1-4烷基中选择,或Y为-C(=O)NRN2-,其中RN2从H、可选择地取代的C1-7烷基或C5-20芳基中选择;R3为可选择地取代的C6芳基基团,连接到另一个可选择地取代的C6芳基基团,如果两个C6芳基基团均为苯环,则两个环之间可能有氧桥,在两个环上的连接处相邻结合;A为单键或C1-3烷基基团;R5为以下之一:(i)羧基;(ii)式(II)的基团;或(iii)式(III)的基团:其中R为可选择地取代的C1-7烷基、C5-20芳基或NRN3RN4,其中RN3和RN4独立地从可选择地取代的C1-4烷基中选择;(iv)四唑-5-基。
查看更多